An open-label, single dose, crossover study to evaluate the relative bioavailability of a new fingolimod formulation (2 x 0.25 mg) in comparison to the Final Market Image (FMI, 0.5 mg) in healthy volunteers.

Trial Profile

An open-label, single dose, crossover study to evaluate the relative bioavailability of a new fingolimod formulation (2 x 0.25 mg) in comparison to the Final Market Image (FMI, 0.5 mg) in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 25 Feb 2013 Status changed from not yet recruiting to completed as reported by Clinical Trials Registry - India.
    • 21 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top